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In June 2013 the Supreme Court held that naturally 
occurring human DNA cannot be patented, but 
synthetically created DNA is patent-eligible. Though a 
major victory for patients’ rights, the holding of 
Association for Molecular Pathology v. Myriad Genetics 
appears to be the latest in a series of restrictions on patents 
and the human body, much to the annoyance of 
biotechnology companies. However, this case should not be 
viewed as the final word in patenting “natural 
phenomena.” Patent claims of genetic material are still 
viable when the claim details a new and useful 
improvement on the naturally occurring product or an 
application of the product to a process. Furthermore, the 
Myriad Court noted that extending the natural products 
rule too far would be against public policy, giving litigators 
room to explore the contours of this rule. 
This Article examines the limits of the Supreme Court’s 
decision and the avenues that potential patent seekers still 
have for making eligible patent claims on naturally 
occurring products and phenomena, as well as the 
processes for identifying such products and phenomena. It 
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highlights the areas where the courts are likely to take a 
hard stance against patent eligibility and where 
opportunities still exist to claim a valid patent in three 
areas. First, though discovery of a natural process in its 
naturally-occurring state is now un-patentable, the Myriad 
holding signals that a variation on this natural state, no 
matter how slight, could make the product eligible for a 
patent under the “new and useful improvements” rule. 
Second, the “application of new processes” rule is 
unchanged by this case. Third, a public policy argument on 
the importance of protecting medical and genetic 
discoveries may be more relevant in light of Myriad’s 
broad holding. 
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In Association for Molecular Pathology v. Myriad Genetics, 
the Supreme Court unanimously reversed the Federal Circuit Court 
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of Appeals’ finding that human DNA was patent-eligible.1 The 
Court instead held that naturally occurring materials, even if first 
“discovered” by a company, do not fall within the scope of 35 
U.S.C. §101 [hereinafter “§101”] and thus cannot be patented.2 In 
a term that saw the Court tackle gay marriage, voting rights, and 
affirmative action, a case concerning patents and biotechnology 
did not stand out as the most vital issue. However, Myriad proves 
both a major victory in the realm of patient-subject rights and a 
cause of concern for the biotechnology industry. 
Myriad has a complicated procedural background and is mired 
in difficult science. However, the Court answered in a brief 
opinion that discovery of genetic material, without significant 
changes to the natural substance, does not satisfy the “new and 
useful” standard under §101. While some fear that this holding will 
greatly restrict the incentives to engage in scientific research, 
Myriad should be seen for the opportunities it provides potential 
patent holders of natural products and the gaps left unaddressed. 
Although discovery alone may not be enough to warrant a patent, 
three doctrines are at a litigator’s disposal in arguing for patent 
eligibility of genetic material. First, the reasoning of Myriad and its 
case history suggest that the courts and the United States Patent 
and Trademark Office will uphold claims detailing new and useful 
improvements, even if they are slight. Second, application of 
discoveries to specific processes was upheld in Myriad. Third, 
public policy arguments against over-applying the reach of the 
naturally occurring exemption can provide a potential fallback 
argument. 
 
I. PROCEDURAL HISTORY AND THE SUPREME COURT’S DECISION 
 
In order to understand the Supreme Court’s straightforward 
holding in Myriad, one must first parse through complicated 
science and a heated series of decisions among the lower courts.  
 
1 133 S. Ct. 2107, 186 L. Ed. 2d 124, 2013 WL 2631062 (June 13, 2013). 
2 Id. 
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A.  Myriad’s Patents 
 
In 1994, Myriad Genetics, Inc. discovered the location and 
sequence of the BRCA 1 and BRCA 2 genes (pronounced brah-
ka).3 These genes and their mutations are strongly linked to an 
increased risk of developing breast and ovarian cancer.4 After 
pinpointing the genes’ locations, Myriad developed a diagnostic 
test to detect the presence of the BRCA mutations in an 
individual’s DNA.5 Myriad was issued the patents for BRCA 1 and 
the diagnostic test in 1997, and for BRCA 2 and the diagnostic test 
in 1998.6 
Additionally, Myriad was able to extract the DNA and 
synthesize a strand of nucleotides referred to as complementary 
DNA (cDNA).7 This synthetic DNA is produced by recreating the 
RNA transcription process but results in a DNA sequence 
distinguishable from the source genetic material.8 As with BRCA 1 
and 2 and the testing, Myriad held patents to exclusively 
synthesize cDNA from the BRCA genes.9 
By 1996, the University of Pennsylvania’s Genetic Diagnostic 
Laboratory (GDL) began providing, for a fee, BRCA 1 and 2 
diagnostic tests, while other labs sent patient samples to GDL for 
separate BRCA tests.10 Myriad responded with letters advising 
GDL researchers that it would enforce its patents, and early 
litigation was resolved with agreements that the labs would 
discontinue activity that potentially infringed on Myriad’s 
patents.11 
3 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 
F.3d 1303, 1313 (Fed. Cir. 2012). This is the appellate decision that the Supreme 
Court overruled. Due to its more detailed and extensive discussion of the facts 
and science, it will be cited for most of the case background. 
4 Id. 
5 BRCA Analysis, MYRIAD GENETICS, http://www.myriad.com/products-
services/hereditary-cancers/bracanalysis/ (last visited Aug. 25, 2014). 
6 Ass’n for Molecular Pathology, 689 F.3d at 1313 n.5. 
7 Id. at 1313–14. 
8 Id. at 1313. 
9 Id. at 1309. 
10 Id. at 1313. 
11 Id. at 1315–16. 
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B.  Road to the Supreme Court 
 
Myriad’s warning letters were merely the beginning of what 
would become a drawn out legal battle. After GDL’s agreement, a 
variety of clinical laboratories, medical societies, individual 
researchers, health-advocacy groups, and individual breast cancer 
patients challenged Myriad’s patents.12 Their suit commenced in 
May 2009 in the District Court for the Southern District of New 
York.13 The complaint alleged violations of 35 U.S.C. §101 
(patentable inventions), the Copyright Clause,14 and the First and 
Fourteenth Amendments.15 
The district court quickly dismissed the constitutional claims 
via the avoidance doctrine, and instead focused on the scope of 35 
U.S.C. §101.16 Examining the patents for the isolated BRCA genes 
and cDNA, the court held that a product of nature is not patentable 
unless the patent holder transforms the original product to the point 
that the new product possesses “markedly different 
characteristics.”17 The court found that Myriad failed to show the 
BRCA genes, in isolated form, were significantly different from 
their natural state.18 Even the patents for the cDNA were 
determined to be naturally occurring products, as they were 
essentially the result of a natural splicing process of pre-mRNA to 
mature mRNA.19 
In regard to the “method” claims of Myriad, the court again 
implemented a strict reading of §101, holding that a process claim 
is patent-eligible only if: “(1) it is tied to a particular machine or 
apparatus, or (2) it transforms a particular article into a different 
12 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 
F. Supp. 2d 181, 186–90 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d 
1329 (Fed. Cir. 2011). 
13 Id. at 186. 
14 U.S. CONST. art. I, § 8, cl. 8. 
15 702 F. Supp. 2d at 184. 
16 Id. at 232. 
17 Id. at 228. 
18 Id. 
19 Id. at 230. 
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state or thing.”20 The court dismissed Myriad’s argument that the 
“analyzing” and “comparing” functions of the isolated DNA 
amounted to a transformation from its natural state, instead finding 
this process to be comparable to mere “data-gathering.”21 
Additionally, the patent Myriad held on a process to compare the 
growth of cancer cells in the presence of different therapeutic 
substances was determined to merely involve the measuring of a 
basic scientific principle and was also deemed un-patentable. As 
such, both Myriad’s DNA and method claims were held invalid.22 
Upon review, the Federal Circuit reversed the district court’s 
invalidation of the isolated DNA patents, affirmed the holding as 
to the method claim for comparing isolated gene sequences, and 
reversed on the process to compare growth of cancer cells claim.23 
Upon a grant of certiorari, the Supreme Court vacated the order 
and remanded to the Federal Circuit in light of its recent decision, 
Mayo Collaborative Services v. Prometheus Laboratories Inc.,24 a 
case which, as discussed below, foreshadowed the final Supreme 
Court decision in Myriad.25  
On its second hearing of the case, the Federal Circuit 
ultimately maintained its original position, holding the DNA 
claims and cancer-growth process patent-eligible but the 
methodology for observing the gene sequences patent-ineligible.26 
Finding both the isolated BRCA genes and the cDNA to have a 
different chemical structure from their original source DNA, the 
court determined these compositional claims fell within the scope 
of §101.27 The court found that the products-of-nature exemption 
used by the lower court was too broad, as any product can be 
20 Id. at 233 (quoting In re Bilski, 545 F.3d 943, 954 (Fed. Cir. 2008)). 
21 Id. at 236. 
22 Id. at 238. 
23 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 
F.3d 1329, 1357 (Fed. Cir. 2011). 
24 132 S. Ct. 1289 (2012). 
25 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 
(2012). 
26 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 
F.3d 1303, 1336 (Fed. Cir. 2012). 
27 Id. at 1332–33. 
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traced back to a naturally occurring source.28 
In regard to the cancer-growth process, the court noted that 
because the method included the “growing of host cells 
transformed” by an altered BRCA 1 gene or a cancer therapeutic, 
the claim on this process was patent-eligible under §101.29 The 
transformative element distinguished this process from a mere 
comparison and analysis of cells.30 Again, the court found no 
transformative process in the analysis of the BRCA sequences.31 
This claim, the court held, merely involved an abstract mental 
process, which could be accomplished by a simple inspection of 
the DNA.32 
 
C.  The Supreme Court’s Decision 
 
Following the Federal Circuit’s opinion, the Supreme Court 
granted certiorari in November 2012 and prepared to hear the case 
on the merits. The Supreme Court issued its decision in June 2013. 
Justice Thomas, authoring the unanimous decision, did away with 
much of the complex scientific background and theories of §101, 
instead asking simply whether Myriad’s patents assert a “new and 
useful . . . composition of matter” or merely a “naturally occurring 
phenomena.”33 
Rejecting the Federal Circuit’s liberal application of 
transformation in the isolation of DNA, the Supreme Court found 
no significant change between the isolated BRCA genes and the 
genes in their original state.34 The Court held that the discovery of 
an important and useful gene, no matter how groundbreaking or 
innovative, does not satisfy §101’s new compositions 
requirement.35 
In contrast, the Court held cDNA is not naturally occurring and 
28 Id. at 1331. 
29 Id. at 1335 (emphasis added). 
30 Id. at 1336. 
31 Id. at 1334. 
32 Id. at 1335. 
33 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2116 (June 13, 2013). 
34 Id. at 2117. 
35 Id. 
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is therefore patent-eligible.36 Despite the cDNA strand containing 
the exons of its original source, the Court determined that this 
synthesized strand does not occur as a natural phenomenon. It is 
only producible in a lab setting.37 
Finally, unlike in the previous decisions, the Court did not 
analyze the method claims. It did, however, suggest that had 
Myriad created an innovative way to manipulate an individual’s 
genes in its search for the BRCA genes, a method patent could 
have been valid.38 Here, since the processes for isolating the genes 
“were well understood, widely used, and fairly uniform insofar as 
any scientist engaged in the search for a gene would likely have 
utilized a similar approach,” the Court found no such novel 
claim.39 
Subsequent cases have generally followed the holding of 
Myriad closely, declining to explore the questions that remain.40 
This lack of exploration also means that the questions on the limits 
of naturally occurring product and method claims have not been 
completely answered. These unanswered questions provide a 
viable option for patent seekers: arguing that a once naturally 
occurring product exists only through man-made manipulation, 
even to the slightest extent, is enough to establish patentability. 
 
II. AN EXAMINATION OF THE “NATURALLY OCCURRING PRODUCT” 
REQUIREMENT AS INTERPRETED BY THE SUPREME COURT 
 
Though §101 appears on its face to be a straightforward rule, a 
deeper examination of its application reveals the statute’s 
limitations that may still be exploited to a patent seeker’s benefit. 
Justice Thomas relied heavily on the plain language of §101 in 
Myriad. However, as in Mayo, the Court again refused to define 
the contours of this section and when a product is no longer 
36 Id. at 2119. 
37 Id. 
38 Id. at 2119–20. 
39 Id. 
40 See Ariosa Diagnostics, Inc. v. Sequenom, Inc., No. C11-06391 SI, 2013 
WL 5863022 (N.D. Cal. Oct. 30, 2013); Oleksy v. General Elec. Co., No. 06 C 
01245, 2013 WL 3233259 (N.D. Ill. June 26, 2013). 
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considered “naturally occurring.” This section will introduce the 
challenges and shortcomings within the statute itself and the court-
created limitations. 
 
A.  Statutory Shortcomings 
 
The statute in question, 35 U.S.C. §101, does not provide 
specific guidance on the limits of patent-eligibility. Rather, the 
statute reads, “Whoever invents or discovers any new and useful 
process, machine, manufacture, or composition of matter, or any 
new and useful improvement thereof, may obtain a patent therefor, 
subject to the conditions and requirements of this title.”41 Based on 
only the statute’s plain language, the Myriad opinion is troubling 
since Myriad did discover a new and useful process. Yet the 
discovery did not satisfy the statutory standard. Additionally, 
Myriad isolated the BRCA genes for testing, but again this was not 
a valid “new or useful improvement.” Thus, on the face of the 
case, Myriad appeared to have satisfied the discovery requirement. 
The Supreme Court’s decision reveals, however, that a patent 
seeker cannot rely on the plain language of §101 alone. As 
guidance through the Court’s interpretation, the patent seeker must 
also consider the common law exceptions to the statute. 
 
B.  Interpreting the Statute’s Court-Created Limits 
 
Recognizing that certain items and phenomena cannot truly be 
“created” for the purposes of patents, the Supreme Court gradually 
identified three subjects over time that are not patentable under 
§101: (1) laws of nature; (2) natural phenomena; and (3) abstract 
ideas.42 However, the Court has also realized that these exceptions 
cannot be overly broad. Since nearly every invention or theory will 
rely on either a law of nature, natural phenomenon, or abstract 
idea, the possibility of “eviscerating” patent law must constantly be 
kept in mind.43 At some point the creative manipulation of a law of 
41 35 U.S.C. § 101 (1952). 
42 Diamond v. Diehr, 450 U.S. 175, 185 (1981). 
43 Mayo Collaborative Servs. v. Prometheus Labs, Inc., 132 S. Ct. 1289, 
1293 (2012). 
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nature, natural phenomena, or abstract idea will need to be 
protected under patent law. The Court declined to specify where 
the line is drawn between the exceptions to §101 and the 
eviscerating, overly-broad interpretations. The Myriad opinion, 
however, hints at when a patented natural product falls within the 
realm of patentability. 
 
III. CREATING VIABLE PATENT CLAIMS POST-MYRIAD 
 
Despite the Supreme Court issuing a very blunt and fairly 
straightforward decision in Myriad, the Court alluded to the 
contours of the Court-created limits of §101 as well as unaffected 
arguments. In the case, Myriad’s arguments about the usefulness of 
its discovery and difficulty in isolating the BRCA genes were not 
enough to satisfy §101. The opinion appears on its face to be so 
broad and insensitive to the nuances of Myriad’s claims that it 
created a sweeping bar against patenting any natural materials. 
However, an analysis of the cDNA claims, application rules, and 
policy concerns reveals that the Court left room for arguments to 
circumvent the basic natural products rule, which the careful 
attorney can utilize in drafting, defending, or challenging patent 
claims. 
 
A.  Deciphering the Limits of New and Useful  
Improvements through cDNA 
 
As noted above, §101 poses a difficult dilemma for patent 
seekers. Natural products cannot be patented, but since everything 
comes from a natural product, what constitutes enough 
manipulation of the natural state to qualify as a patentable product 
under §101? The Court’s short analysis of cDNA suggests that the 
required transformation from natural to unnatural may in fact be 
minimal. 
Immediately following Myriad, the United States Patent and 
Trademark Office issued a memorandum to its staff directing 
examiners to reject product claims “drawn solely to naturally 
occurring nucleic acids or fragments thereof, whether isolated or 
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not . . . .”44 However, the Office recognized that claims 
demonstrating that the naturally occurring matter has been altered 
(“e.g., a man-made variant sequence”) are eligible.45 The Office 
later issued additional guidance to the Patent Examining Corps, 
directing that all claims that recite or involve a law of nature, 
natural phenomenon, or natural product be rejected unless the 
claims also recite something “significantly different” than the 
judicial exception.46 The Office suggested two general ways in 
which a significant difference can manifest: (1) the claim adds 
elements or steps to the judicial exception that “practically apply 
the judicial exception in a significant way” or (2) the claim states 
some features or steps demonstrating the claimed subject matter is 
“markedly different” from the natural product or phenomena.47 
Additionally, the Office listed six factors that suggest a claim is 
eligible and six that suggest it is ineligible. Two of these factors 
are of particular relevance to patent claims involving genetic 
material: “factor (a),” where the claim is a product that appears to 
be merely a natural product but demonstrates that it is non-
naturally occurring and markedly different from the natural 
product (weighing in favor of eligibility), or “factor (g),” where the 
claim recites a natural product or something that resembles a 
natural product but is not markedly different.48 Thus, in applying 
for a patent, the most significant step an applicant can take is 
stressing the variation that has occurred to the natural product. 
However, these guidance memos do little to clarify what 
constitutes a marked or significant difference in the claimed 
product. 
Rather, a determination of the degree necessary to satisfy this 
44 Memorandum from Andrew H. Hirshfeld, Deputy Comm’r for Patent 
Examination Policy, U.S. Patent and Trademark Office, to the Patent Examining 
Corps (June 13, 2013), available at http://www.uspto.gov/patents/law/exam/ 
myriad_20130613.pdf. 
45 Id. 
46 Memorandum from Andrew H. Hirshfeld, Deputy Comm’r for Patent 
Examination Policy, U.S. Patent and Trademark Office, to the Patent Examining 
Corps (Mar. 14, 2014), available at http://www.uspto.gov/patents/law/exam/ 
myriad-mayo_guidance.pdf. 
47 Id. at 3–4. 
48 Id. at 4. 
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“significantly different” standard is best clarified by the Myriad 
decision and previous natural product cases. Central to the Court’s 
rejection of Myriad’s BRCA patents was the idea that the company 
had not made any new or useful improvements to the original gene 
sequence.49 The BRCA genes isolated from the individual’s DNA 
were structurally the same product as the genes in their natural 
state. Conversely, the Court in Diamond v. Chakrabarty found that 
when scientists added plasmids to a bacterium, which broke down 
various components of a bacterium, the resulting bacterium was 
patentable.50 The process of breaking down the bacterium was not 
the claim in dispute, but the resulting product was.51 The Court 
found that the final bacterium was the result of “human ingenuity,” 
having “a distinctive name, character [and] use.”52 Thus, 
Chakrabarty indicates that the final product resulting from the 
natural reaction between two other natural products meets the 
patentability standard. 
While the extent of the change has not been defined, the 
Myriad Court’s examination of the cDNA claims provides insight 
on how little the change really needs to be. The Court found that 
cDNA easily meets the threshold for §101, despite the petitioner’s 
arguments that the basic structure of cDNA is “dictated by nature, 
not by the lab technician.”53 Since the exon-only sequence does 
not occur in nature, the Court found the cDNA patents to be 
valid.54 The holdings of Myriad and Chakrabaty suggest that all 
that is required to meet the new and useful improvement standard 
for natural products is a change that could not occur but for the 
patent seeker’s intervention or process. 
Without any firm measurement by the Court, even the slightest 
variation could meet the standard under §101 as long as the change 
does not occur as a natural process. Litigators defending or 
challenging future patent claims on similar grounds should seize 
49 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2117 (June 13, 2013). 
50 447 U.S. 303, 309–10 (1980). 
51 Id. 
52 Id. 
53 133 S. Ct. at 2119. 
54 Id. 
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upon this ambiguity, stressing the uniqueness of the holder’s 
claims, or lack thereof. In particular, focus should be drawn to the 
differences between the naturally occurring state and the processed 
result. 
While Myriad relied heavily on its discovery of the BRCA 
genes, the Court’s decision and the Patent Office’s subsequent 
guidance documents may result in a shift away from the discovery 
arguments. Discovery, no matter how groundbreaking, is merely a 
noteworthy accomplishment that affords little legal protection 
post-Myriad. Instead of attempting to protect their discovery, 
patent seekers will likely find more success arguing the validity of 
the resulting product. Patent seekers might even forgo method 
claims, especially those involving well-known scientific processes, 
and stress the new and useful improvements on a naturally 
occurring product in their patent requests. 
 
B.  “Application of New Processes” Patents Remain Valid 
 
Patent seekers should also not ignore the importance of making 
application claims, an opportunity the Supreme Court and Federal 
Circuit each believed Myriad had squandered.55 The Supreme 
Court suggested that Myriad was in an advantageous position to 
claim new applications of its knowledge about BRCA 1 and 2.56 
The Federal Circuit noted that Myriad could claim application of 
the BRCA discoveries especially in its fight against breast 
cancer.57 However, to a future patent seeker, an application claim 
will be easier said than done. The claim will have to state a specific 
application of the discovery, but such a statement does not 
guarantee that the discovery, process, or modified product will be 
protected by patent law.58 Practitioners should keep in mind that 
55 Id. at 2120; Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 689 F.3d 1303, 1349 (Fed. Cir. 2012). 
56 133 S. Ct. at 2120 (quoting 689 F.3d at 1349). 
57 689 F.3d at 1349. 
58 See Memorandum from Andrew H. Hirshfeld, Deputy Comm’r for Patent 
Examination Policy, U.S. Patent and Trademark Office, to the Patent Examining 
Corps (Mar. 14, 2014), available at http://www.uspto.gov/patents/ 
law/exam/myriad-mayo_guidance.pdf (stating that a natural product claim can 
be analyzed with only factors (a) and (g) while other claims, including 
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the Court separated the application claims from the product 
claim.59 
For example, in Myriad, while the BRCA genes could never 
have been patentable, the patent claim would be acceptable had it 
made a new or useful application claim. Conversely, one could 
make a valid patentable product claim, but the claim for the 
application of the product, if relying upon well-known processes, 
would not be eligible. Thus the patent seekers should recognize 
that product and application claims are not necessarily bound 
together and that a claim for application may still protect discovery 
even if the product claim is deemed ineligible. 
 
C.  Limits of the Exceptions: How Far Is Too Far? 
 
If significant changes to a product of nature are impractical or 
impossible and an application claim is futile, a policy argument 
still remains a powerful tool in defending a patent. Though the 
Supreme Court raised the issue of whether an overly broad reading 
of §101 will detrimentally impact future patent claims, the line is 
yet to be definitively drawn. Though such arguments have no place 
in applications for patents, this issue will continue to be an 
important argument for the courtroom. 
One important aspect of the policy argument is the difficulty of 
discovery. Even the Supreme Court missed the opportunity to 
distinguish between easily made discoveries of natural products, 
phenomenon, or abstract ideas and discoveries that involve a far 
more nuanced approach. The strict adherence to the plain language 
of §101 does not allow for such distinctions. In Mayo, decided 
shortly before the final Myriad decision, the Court equated (at least 
in terms of patent eligibility) medical discoveries to discoveries 
based on basic observations, noting that “a new plant found in the 
wild is not patentable subject matter.”60 Unlike a person who 
stumbles upon a plant and discovers it has medicinal purposes 
through mere chance, genetics is a very deliberate and expensive 
application claims, should be analyzed with the remaining factors). 
59 133 S. Ct. at 2119. 
60 Mayo Collaborative Servs. v. Prometheus Labs, Inc., 132 S. Ct. 1289, 
1293 (2012). 
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science. Individuals do not merely come across genes in the course 
of their day. Trained scientists with advanced equipment and 
funding make concentrated efforts to seek out such phenomena. 
Yet the Court refused to make such a distinction and essentially 
held the geneticist’s discovery to the same standard as the lucky 
individual who discovers the plant. 
Another issue is the potential chilling effect on the biotech 
industry. The basic principles of patent law are that patent law 
needs first to seek to “foster and reward” inventor and second to 
promote disclosure of inventors’ ideas to stimulate further 
innovations.61 As the field of genetics continues to grow, the courts 
will have to continue to keep these principles in mind. While 
patient rights will always remain a valid concern, the fostering of 
scientific discovery should not be ignored. In light of the broad 
holding of Myriad, this public policy argument against stifling 
discovery may carry increasing weight and, as such, courts may be 




Given the relatively recent publication of Myriad, application 
of the case has been slow in lower courts. Nonetheless, the 
importance and profitability of scientific, and specifically genetic, 
research requires that the courts draw a line so as to not completely 
stifle the field. However, this need must be balanced with patient 
rights. The Myriad decision offers insights into both these 
arguments. As long as a claim attempts to patent genetic material 
in its natural state, the courts will invalidate the patent for the 
foreseeable future. However, the validation of the cDNA patents 
suggests that even the slightest changes to the natural state can 
suffice for patentability under §101. Additionally, Myriad does not 
appear to have had an effect on method or application claims. 
Thus, practitioners are still left with the ability to patent genetic 
materials as long as the claim places emphasis on variations on the 
product, method, or unique application of a process. Finally, the 
61 Robert A. Matthews Jr., 1 Annotated Patent Digest §1:2: Purposes of the 
patent system (updated July 2014). 
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public policy argument against overly broad interpretations of 
§101 can continue to be argued with attention to the necessity for 




 Keep in mind policy arguments about the overreach of the 
law and argue the necessity of protecting and promoting 
innovation. 
 When drafting a patent application, stress that the new 
product cannot occur in nature and only exists through the 
process rendered by the patent seeker. 
 Put additional emphasis on the description of utility and the 
transformative elements of the inventive method or 
composition as an application of a natural law. 
 Avoid claims that only have “comparing” or “determining” 
elements associated with a natural correlation. 
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